Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

Abstract In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although sca...

Full description

Bibliographic Details
Main Authors: Luigi Cirillo, Chiara Somma, Marco Allinovi, Alfredo Bagalà, Giuseppe Ferro, Elio Di Marcantonio, Stefania Bellelli, Lorenzo Antonio Dallari, Piercarlo Ballo, Pietro Claudio Dattolo
Format: Article
Language:English
Published: Nature Publishing Group 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-86769-z

Internet

https://doi.org/10.1038/s41598-021-86769-z

Similar Items